Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 3/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | CRHBP | P24387 | 1/20 | 0.47 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2403545 | 1.00 | ACHE (1.00) | ACHESLC6A4GAAMAPTCRHBP | |
| SCHEMBL3864612 | 1.00 | ACHE (1.00) | ACHESLC6A4GAAMAPTCRHBP | |
| Hydrochloric Acid SCHEMBL3863985 | 0.99 | ACHE (0.98) | ACHESLC6A4GAAMAPTCRHBP | |
| Hydrochloric Acid SCHEMBL3863983 | 0.99 | ACHE (0.98) | ACHESLC6A4GAAMAPTCRHBP | |
| Hydrochloric Acid SCHEMBL3873759 | 0.99 | ACHE (0.98) | ACHESLC6A4GAAMAPTCRHBP | |
| Fumaric Acid SCHEMBL3865189 | 0.94 | ACHE (0.89) | ACHESLC6A4GAAMAPTCRHBP | |
| Fumaric Acid SCHEMBL29416797 | 0.94 | ACHE (0.89) | ACHESLC6A4GAAMAPTCRHBP | |
| Fumaric Acid SCHEMBL3865190 | 0.94 | ACHE (0.89) | ACHESLC6A4GAAMAPTCRHBP | |
| Fumaric Acid SCHEMBL3865183 | 0.94 | ACHE (0.89) | ACHESLC6A4GAAMAPTCRHBP | |
| Hydrochloric Acid SCHEMBL3873670 | 0.94 | ACHE (0.88) | ACHESLC6A4GAAMAPTCRHBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2586436-A1 | Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitor | Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR) | 2013-05-01 | — | — | EP | claimed |
| US-7504437-B2 | Benzylamine analogues | BTG INTERNATIONAL LIMITED (GB) | 2009-03-17 | — | — | US | claimed |
| US-20090036487-A1 | Combinations | PFIZER INC. | 2009-02-05 | — | — | US | claimed |
| EP-1362844-B1 | BENZYLAMINE ANALOGUE | BTG INT LTD (GB) | 2007-12-05 | — | — | EP | claimed |
| EP-1667722-A1 | COMBINATIONS OF ALPHA-2-DELTA LIGANDS AND ACETYLCHOLINESTERASE INHIBITORS | Pfizer Limited (GB) | 2006-06-14 | — | — | EP | claimed |
| WO-2005027975-A1 | COMBINATIONS OF ALPHA-2-DELTA LIGANDS AND ACETYLCHOLINESTERASE INHIBITORS | PFIZER LIMITED (GB) | 2005-03-31 | — | — | WO | claimed |
| US-20050065176-A1 | Combinations | FIELD MARK JOHN (GB) | 2005-03-24 | — | — | US | claimed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| US-10765670-B2 | Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitors | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2020-09-08 | — | — | US | disclosed |
| EP-2773337-B1 | USE OF ANTI-CONNEXIN AGENTS FOR ENHANCING THE THERAPEUTIC EFFECT OF ACETYLCHOLINESTERASE INHIBITORS | COMMISSARIAT ENERGIE ATOMIQUE (FR) | 2018-09-19 | — | — | EP | disclosed |
| US-20180177773-A1 | USE OF ANTI-CONNEXIN AGENTS FOR ENHANCING THE THERAPEUTIC EFFECT OF ACETYLCHOLINESTERASE INHIBITORS | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2018-06-28 | — | — | US | disclosed |
| EP-2533645-B1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | UNIV JOHNS HOPKINS (US) | 2016-07-27 | — | — | EP | disclosed |
| EP-1667722-A1 | COMBINATIONS OF ALPHA-2-DELTA LIGANDS AND ACETYLCHOLINESTERASE INHIBITORS | Pfizer Limited (GB) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005112946-A1 | METHOD FOR IMPROVING COGNITIVE FUNCTION BY CO-ADMINISTRATION OF A GABAB RECEPTOR ANTAGONIST AND AN ACETYLCHOLINESTERASE INHIBITOR | THE JOHNS HOPKINS UNIVERSITY (US) | 2005-12-01 | — | — | WO | disclosed |
| US-20050267077-A1 | Method for improving cognitive function by co-administration of a GABAB receptor antagonist and an acetylcholinesterase inhibitor | JOHNS HOPKINS UNIVERSITY (US) | 2005-12-01 | — | — | US | disclosed |
| WO-2005027975-A1 | COMBINATIONS OF ALPHA-2-DELTA LIGANDS AND ACETYLCHOLINESTERASE INHIBITORS | PFIZER LIMITED (GB) | 2005-03-31 | — | — | WO | disclosed |
| US-20050065176-A1 | Combinations | FIELD MARK JOHN (GB) | 2005-03-24 | — | — | US | disclosed |
| US-20040067981-A1 | Acetylcholinesterase inhibitor; Alzheimer's diseases, Hubtington disease, antidepressants | SANKYO COMPANY, LIMITED (JP) | 2004-04-08 | — | — | US | disclosed |
| EP-1362844-A1 | BENZYLAMINE ANALOGUE | Sankyo Company, Limited (JP) | 2003-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036487-A1 | Combinations | CHRNE, CHRND, CHRNG | ACHE 7/4885SLC6A4 2004/4885GAA 2461/4885 |
| US-20040067981-A1 | Acetylcholinesterase inhibitor; Alzheimer's diseases, Hubtington disease, antidepressants | ACHE, BACE1, CHRNA6 | ACHE 1/4885SLC6A4 25/4885GAA 433/4885 |
| US-20050065176-A1 | Combinations | CHRNE, CHRND, CHRNG | ACHE 7/4885SLC6A4 2004/4885GAA 2461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.